Celgene (CELG) Given a $112.00 Price Target by Cantor Fitzgerald Analysts
Cantor Fitzgerald set a $112.00 price target on Celgene (NASDAQ:CELG) in a research report sent to investors on Monday. The brokerage currently has a hold rating on the biopharmaceutical company’s stock.
A number of other research firms also recently issued reports on CELG. BMO Capital Markets lifted their price objective on Celgene from $148.00 to $155.00 and gave the stock an outperform rating in a research note on Friday, November 17th. Oppenheimer reaffirmed a buy rating and issued a $170.00 price objective on shares of Celgene in a research note on Friday, October 20th. Vetr raised Celgene from a buy rating to a strong-buy rating and set a $144.39 price objective on the stock in a research note on Monday, October 23rd. Cann reaffirmed a buy rating on shares of Celgene in a research note on Thursday, October 26th. Finally, Morgan Stanley raised Celgene from an underweight rating to an equal weight rating in a research note on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $136.21.
Shares of Celgene (CELG) opened at $108.24 on Monday. The stock has a market capitalization of $85,187.70, a P/E ratio of 16.91, a P/E/G ratio of 0.84 and a beta of 1.78. Celgene has a 12 month low of $94.55 and a 12 month high of $147.17. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65.
Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the company earned $1.58 EPS. equities analysts forecast that Celgene will post 6.67 earnings per share for the current fiscal year.
In other news, insider Terrie Curran sold 1,727 shares of Celgene stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the transaction, the insider now owns 3,925 shares in the company, valued at approximately $564,768.25. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.95% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Todd Asset Management LLC bought a new stake in Celgene during the 1st quarter valued at $17,130,000. Groesbeck Investment Management Corp NJ raised its position in Celgene by 3.5% during the 1st quarter. Groesbeck Investment Management Corp NJ now owns 4,455 shares of the biopharmaceutical company’s stock valued at $554,000 after purchasing an additional 150 shares in the last quarter. Marcus Capital LLC raised its position in Celgene by 1.5% during the 1st quarter. Marcus Capital LLC now owns 11,550 shares of the biopharmaceutical company’s stock valued at $1,437,000 after purchasing an additional 175 shares in the last quarter. Independent Advisor Alliance raised its position in Celgene by 46.3% during the 1st quarter. Independent Advisor Alliance now owns 6,003 shares of the biopharmaceutical company’s stock valued at $745,000 after purchasing an additional 1,899 shares in the last quarter. Finally, Premier Asset Managment LLC raised its position in Celgene by 5.0% during the 1st quarter. Premier Asset Managment LLC now owns 123,107 shares of the biopharmaceutical company’s stock valued at $15,318,000 after purchasing an additional 5,840 shares in the last quarter. Institutional investors own 80.16% of the company’s stock.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.